{
    "thesis_theoretical": [
        {
            "Thesis0": "The influencer suggests that the company's strong fundamentals and high growth rate are the key reasons for its impressive returns."
        },
        {
            "Thesis1": "The influencer also suggests that despite the significant increase in the stock's price, it could still be undervalued given its PE ratio and PEG ratio."
        },
        {
            "Thesis2": "The influencer believes that the company has the potential to become a mid-cap or large-cap stock in the future."
        }
    ],
    "thesis_quantitative": [
        {
            "Thesis0": "In the last five years, the stock has given close to 2200% returns."
        },
        {
            "Thesis1": "In the last few years, the company's revenues have been growing at a rate of 26-30%, and its earnings per share have been growing at a rate of 44-32%."
        },
        {
            "Thesis2": "The stock's price has increased from 55 Rupees to roughly 700 rupees."
        },
        {
            "Thesis3": "The stock's PE ratio is currently 19, compared to the Nifty Pharma PE of roughly 31."
        },
        {
            "Thesis4": "The stock's PEG ratio is currently 0.27."
        }
    ],
    "username": "Rahul Jain"
}